



**Ruxandra Draghia-Akli**  
**MD PhD**

Director Health  
DG Research & Innovation


# Towards a new PPP on biomedical Research and Innovation under Horizon 2020

HORIZON 2020

A graphic for the Horizon 2020 program. The word "HORIZON 2020" is written in large, white, sans-serif capital letters. The letter "O" in "HORIZON" is replaced by a realistic, glowing globe of the Earth. The background is a vibrant blue with a lens flare effect emanating from behind the globe, and a curved horizon line at the bottom.

Research and  
Innovation

# R&D investment: fuel for the economy



# What is Horizon 2020

- **Commission proposal for a 80 billion euro research and innovation funding programme (2014-2020)**
- **A core part of Europe 2020, Innovation Union & European Research Area:**
  - **Responding to the economic crisis** to invest in future jobs and growth
  - **Addressing people's concerns** about their livelihoods, safety and environment
  - **Strengthening the EU's global position** in research, innovation and technology



# Three Priorities:

- 1. Excellent science (€24.5 billion)**
- 2. Industrial leadership (€17.9 billion)**
- 3. Societal challenges (€31.7 billion)**

# Priority 3. Societal Challenges

*Why:*

- Concerns of citizens and society/EU policy objectives (climate, environment, energy, transport etc) cannot be achieved without innovation
- Breakthrough solutions come from multi-disciplinary collaborations, including social sciences & humanities
- Promising solutions need to be tested, demonstrated and scaled up

# Proposed Funding (million euro, 2014-2020)

Health, demographic change and wellbeing	8 033
Food security, sustainable agriculture, marine and maritime research & the bioeconomy	4 152
Secure, clean and efficient energy*	5 782
Smart, green and integrated transport	6 802
Climate action, resource efficiency and raw materials	3 160
Inclusive, innovative and secure societies	3 819

***\*Additional €1 788m for nuclear safety and security from the Euratom Treaty activities (2014-2018). Does not include ITER.***

# Simplification

- **Single set of** simpler and more coherent participation **rules**
- New **balance between trust and control**
- Moving from several **funding rates** for different beneficiaries and activities to just two
- Replacing the four methods to calculate overhead or «indirect costs» with a **single flat rate**
- Major simplification under the **forthcoming financial regulation**
- **Successful applicants to get working more quickly:** reduction of average time to grant

# Next Steps

- Ongoing:** Parliament and Council negotiations on the basis of the Commission proposals
- Ongoing:** Parliament and Council negotiations on EU budget 2014-2020 (including overall budget for Horizon 2020)
- Ongoing:** Final calls under 7th Framework Programme for research to bridge gap towards Horizon 2020
- Mid 2013:** Adoption of legislative acts by Parliament and Council on Horizon 2020
- 1/1/2014:** **Horizon 2020 starts, launch of first calls**



# Horizon 2020 and Partnering

## ***Public-private partnerships (PPPs):***

- *Through Joint Technology Initiatives or other formal structures (Art. 187)*
- *Through contractual agreements, which provide inputs for work programmes*
- *Only when criteria met, e.g. clear commitments from private partners*

***Also: public-public partnerships (e.g. ERA-Nets, Joint Programming Initiatives)***

# Moving Forward with a PPP in Innovative Health Research

→ *Will be based on experience from IMI*

## Criteria to be fulfilled

- (a) Added value of action at Union level;
- (b) Scale of impact on industrial competitiveness, sustainable growth and socio-economic issues;
- (c) Long-term commitment from all partners based on a shared vision and clearly defined objectives;
- (d) Scale of the resources involved and the ability to leverage additional investments in research and innovation;
- (e) Clear definition of roles for each of the partners and agreed key performance indicators over the period chosen.

## Key Processes / Timelines

- *For a new PPP implemented under Article 187 of the TFEU a legislative proposal from the Commission will be required*
- *Impact assessment exercise ongoing*
- *Closely following the consultations about the rules for participation in Council and Parliament*
- *Preparation of the model financial regulation for "light union bodies"*
- *Preparations for making a legislative proposal next year, after adoption of Horizon 2020*

# Status of Preparations for Impact Assessment for Life Science PPP under Horizon 2020

- *Online public consultation closed 4 October, 134 replies; online consultation of IMI participants closed 4 October; 239 replies, representing 42.9% of unique participants*
- *Targeted consultation of stakeholders*
- *Appointment of expert group to support Commission in preparation of impact assessment: F. Gvillo (USA – chair), N. Safrany (FR – rapporteur), M. Aguirre (ES), M. Szumowski (PL), J. Knowles (UK)*

# Targeted Stakeholder Consultations through Meetings/Conferences (1)

- *CEOs of EFPIA companies with Commissioner Geoghegan-Quinn on 26 June*
- *Global heads of research of EFPIA companies, as well as regulators, academic investigators and representatives of WHO on 3 September*
- *Representatives of SMEs on 19 September*
- *European coordination committee of the radiological, electromedical and health care IT industry (COCIR) on 19 September 2012*

# Targeted Stakeholder Consultations through Meetings/Conferences (2)

- *Patient representatives through the EFPIA Patient Think Tank on 28 September 2012*
- *Today's IMI SRG meeting and IMI conference in the context of the Cyprus presidency event InnoVaHealth conference (11 through 13 October)*
- *Regulators European Medicines Agency (EMA) and the Food and Drug Administration of the USA (FDA) on 7 November*



# Thank you for your attention!

**Find out more:**

[www.ec.europa.eu/research/horizon2020](http://www.ec.europa.eu/research/horizon2020)